Patents Assigned to Biosite Diagnostics Incorporated
-
Patent number: 6271040Abstract: The assay devices, assay systems and device components of this invention comprise at least two opposing surfaces disposed a capillary distance apart, at least one of which is capable of immobilizing at least one target ligand or a conjugate in an amount related to the presence or amount of target ligand in the sample from a fluid sample in a zone for controlled fluid movement to, through or away the zone. The inventive device components may be incorporated into conventional assay devices with membranes or may be used in the inventive membrane-less devices herein described and claimed. These components include flow control elements, measurement elements, time gates, elements for the elimination of pipetting steps, and generally, elements for the controlled flow, timing, delivery, incubation, separation, washing and other steps of the assay process.Type: GrantFiled: July 30, 1997Date of Patent: August 7, 2001Assignee: Biosite Diagnostics IncorporatedInventor: Kenneth Francis Buechler
-
Patent number: 6037455Abstract: The present invention is directed to novel propoxyphene derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to propoxyphene and propoxyphene metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.Type: GrantFiled: November 9, 1992Date of Patent: March 14, 2000Assignee: Biosite Diagnostics IncorporatedInventor: Kenneth F. Buechler
-
Patent number: 5947124Abstract: The present invention relates to methods for determining the time of a myocardial infarction in a patient by measuring the ratio of oxidized to reduced troponin I in a blood sample obtained from the patient. This ratio is measured through the use of two or more distinct components which specifically bind oxidized troponin I, reduced troponin I, and/or both forms of troponin I present in the blood sample. Each distinct component may be an antibody or an antibody fragment. The measured ratio reflects the time elapsed from the time of the myocardial infarction.Type: GrantFiled: March 21, 1997Date of Patent: September 7, 1999Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth Francis Buechler, Paul H. McPherson
-
Patent number: 5939272Abstract: Assay methods for performing non-competitive ligand-receptor assays, where said assays provide a sensible result when the target ligand identified by the assay is present at a concentration greater than a defined threshold concentration. The threshold concentration can be selected to be the upper limit of a normal range of values for a target ligand in a sample, so that an assay in accordance with the invention provides a sensible result only when the target ligand is present at elevated levels.Type: GrantFiled: June 11, 1997Date of Patent: August 17, 1999Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, Gunars E. Valkirs, Richard R. Anderson
-
Patent number: 5922615Abstract: Devices for use in heterogeneous ligand-receptor assays, having a porous member in contact with a nonabsorbent textured surface, where the surface texturing is such that a capillary network is formed when in fluid communication with the porous member. More particularly, these devices comprise:(a) a porous member having (i) at least one binding agent capable of immobilizing at least one target ligand on the porous member from a fluid sample in at least one zone and (ii) a means for detecting the presence or amount of said target ligand as a result of the assay process; and(b) a nonabsorbent member in fluid communication with the porous member, the nonabsorbent member forming at least one capillary with the porous member so that when sample, alone or in combination with other fluids, is added to the porous member, fluid is drawn through the porous member.Type: GrantFiled: June 2, 1995Date of Patent: July 13, 1999Assignee: Biosite Diagnostics IncorporatedInventors: Mark R. Nowakowski, Kenneth F. Buechler, Richard R. Anderson, Gunars E. Valkirs
-
Patent number: 5824799Abstract: Water soluble hybrid phthalocyanine derivatives useful in competitive and noncompetitive assays immunoassays, nucleic acid and assays are disclosed and claimed having (1) at least one donor subunit with a desired excitation peak; and (2) at least one acceptor subunit with a desired emission peak, wherein said derivative(s) is/are capable of intramolecular energy transfer from said donor subunit to said acceptor subunit. Such derivatives also may contain an electron transfer subunit. Axial ligands may be covalently bound to the metals contained in the water soluble hybrid phthalocyanine derivatives. Ligands, ligand analogs, polypeptides, proteins and nucleic acids can be linked to the axial ligands of the dyes to form dye conjugates useful in immunoassays and nucleic acid assays.Type: GrantFiled: March 22, 1996Date of Patent: October 20, 1998Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, Joseph B. Noar, Lema Tadesse
-
Patent number: 5795725Abstract: Assays and antibodies are disclosed for the detection and quantitation of cardiac specific troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I and T and the binary and ternary complexes may be related to the metabolic state of the heart. More specifically, immunoassays for determining the presence or amount of free, binary and ternary complexes of troponin I and T are claimed.Type: GrantFiled: April 18, 1995Date of Patent: August 18, 1998Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, Paul H. McPherson
-
Patent number: 5763189Abstract: Particles comprising an energy donor as a first component and a fluorescent dye as a second component positioned in said particles at an energy exchanging distance from one another, wherein the two components have a Stokes shift of greater than or equal to 50 nm, said particle having bound on its surface, a protein, polypeptide, nucleic acid, nucleotide or protein containing ligand analogue are disclosed and claimed. In addition, novel fluorescent dyes are described which exhibit intramolecular energy transfer for use to label various molecules, proteins, polypeptides, nucleotides and nucleic acids or to incorporate into particles.Type: GrantFiled: September 23, 1994Date of Patent: June 9, 1998Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, J. Barry Noar, Lema Tadesse
-
Patent number: 5710256Abstract: The present invention is directed to novel methadone derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to methadone and methadone metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.Type: GrantFiled: April 3, 1995Date of Patent: January 20, 1998Assignee: Biosite Diagnostics IncorporatedInventor: Kenneth F. Buechler
-
Patent number: 5679526Abstract: This invention is directed to a ligand-receptor assay for determining the presence of at least one target ligand, capable of competing with a ligand analogue conjugate for binding sites available on a ligand receptor, said ligand analogue conjugate comprising at least one ligand analogue coupled to a colloidal gold particle, in a fluid sample suspected of containing said target ligand comprising the steps of:a. contacting said fluid sample with said ligand analogue conjugate and said ligand receptor to form a homogeneous reaction mixture, the relative amounts of said ligand analogue conjugate and said ligand receptor being selected such that in the absence of said target ligand and subsequent to substantially equilibrium binding in said reaction mixture, substantially all of said ligand analogue conjugate is bound to said ligand receptor such that no unbound ligand analogue conjugate is detected as a result of the assay method;b.Type: GrantFiled: August 1, 1994Date of Patent: October 21, 1997Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, Gunars E. Valkirs, Richard R. Anderson
-
Patent number: 5610283Abstract: The present invention is directed to novel opiate derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to the opiates and opiate metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.Type: GrantFiled: February 15, 1995Date of Patent: March 11, 1997Assignee: Biosite Diagnostics IncorporatedInventor: Kenneth F. Buechler
-
Patent number: 5470997Abstract: The present invention is directed to novel amphetamine derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to amphetamine and amphetamine metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.Type: GrantFiled: April 6, 1992Date of Patent: November 28, 1995Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, Joseph B. Noar, Si S. Moi
-
Phencyclidine derivatives and protein and polypeptide phencyclidine derivative conjugates and labels
Patent number: 5331109Abstract: The present invention is directed to novel PCP derivatives which are synthesized for the covalent attachment to antigens or receptors (proteins or polypeptides) for the preparation of antibodies or receptors to PCP and PCP analogue metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.Type: GrantFiled: April 6, 1992Date of Patent: July 19, 1994Assignee: Biosite Diagnostics IncorporatedInventor: Kenneth F. Buechler -
Patent number: 5302703Abstract: The present invention is directed to novel THC derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to the THC metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.Type: GrantFiled: March 17, 1993Date of Patent: April 12, 1994Assignee: Biosite Diagnostics IncorporatedInventors: Kenneth F. Buechler, Si S. Moi